Form 4: Edwards Lifesciences Executive Executes Stock Option Plan

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, exercised and sold 620 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel J. Lippis, CVP of TAVR, exercised 620 stock options at a strike price of $72.68.
• Following the exercise, the reporting person sold the 620 shares at a market price of $81.14.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026.
• The reporting person retains 40,410.9103 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine, pre-planned executive equity management.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a key executive, though the volume is relatively small compared to total holdings.

Risks

• None identified; this is a routine disclosure of executive compensation and equity management.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine 10b5-1 trading plan activity by medical device executives is standard practice for liquidity and diversification and generally does not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice among S&P 500 companies to avoid potential insider trading concerns.
• The scale of the transaction is consistent with typical executive compensation and equity liquidation patterns in the medical technology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small fraction of the executive's total holdings.

Next Steps

• None mentioned.

Key Dates

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, TAVR, Stock Options, 10b5-1